AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin.
ABBV
· Healthcare · Drug Manufacturers - General
· Market cap $462.37B
QuantHub Original Research · Updated 2026-09-15
·
High QualityHigh-tier business, very_expensive-tier valuation; 1.0% downside to $259.04 fair value limits the risk-adjusted return despite 16.9% upside to the $306 analyst target.Fair Value
ABBV is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Scaling Phase
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a 35.9% decline in Humira revenue to $756 million. Business quality is tempered by post-Humira concentration, sizable leverage and the dilutive $10.9 billion Apogee acquisition. At $261.70, shares trade at 73.4x trailing earnings, 23.55x free cash flow and 24.8x EV/EBITDA, and screen as very expensive versus their five-year valuation history; however, the $259.04 fair value estimate implies only 1.0% downside to fair value, while a Strong Buy analyst consensus target of $306 implies 16.9% upside. The stock therefore appears approximately fairly valued on the supplied fair-value framework rather than materially mispriced.
AbbVie trades at a demanding 73.4x trailing P/E, 23.55x P/FCF and 24.8x EV/EBITDA, and its very_expensive valuation regime indicates a premium to its own five-year historical trading range. The market is pricing sustained execution from Skyrizi, Rinvoq and neuroscience to offset rapid Humira erosion, while also discounting eventual strategic benefits from Apogee despite expected adjusted-EPS dilution of $0.14 in 2026 and approximately $0.46 in 2027. Sentiment remains constructive, with a Strong Buy consensus and a $306 average target implying 16.9% upside, but this is materially more optimistic than the supplied $259.04 fair value estimate, which indicates 1.0% downside to fair value.
12–18 Month Outlook
Over the next 18 months, AbbVie will likely be judged primarily on whether Skyrizi and Rinvoq can sustain growth sufficient to offset continuing Humira biosimilar erosion, which was 35.9% year over year in Q2 2026. Neuroscience is a second growth pillar after 20.3% Q2 revenue growth, but oncology and aesthetics need improvement after a 1.5% decline and 0.3% growth, respectively. The completed Apogee acquisition expands the late-stage immunology pipeline but adds integration, leverage and expected EPS dilution through 2027, so evidence of clinical execution and strategic fit will be important. With shares at $261.70 versus $259.04 fair value, valuation downside remains a meaningful risk if growth moderates or acquisition benefits take longer to emerge.
Bull vs Bear
Bull Case
Q2 2026 revenue increased 10.2% year over year to $16.990 billion, led by 15.1% immunology growth to $8.786 billion.
Skyrizi revenue grew 24.4% year over year to $5.505 billion and Rinvoq revenue grew 24.5% to $2.525 billion in Q2 2026, providing substantial offsets to declining Humira sales.
Neuroscience revenue rose 20.3% year over year to $3.228 billion in Q2 2026, supported by Vraylar revenue of $1.071 billion, Botox Therapeutic revenue of $1.042 billion and combined Ubrelvy/Qulipta revenue of $742 million.
AbbVie maintained FY2026 adjusted EPS guidance of $13.87 to $14.07 after completing the Apogee acquisition, indicating that operating performance is absorbing much of the transaction-related dilution.
The $306 average analyst target implies 16.9% upside from the $261.70 current price, and consensus remains Strong Buy.
Bear Case
Humira revenue fell 35.9% year over year to $756 million in Q2 2026 because of biosimilar competition, and continued erosion could outpace growth in successor immunology products.
The stock trades at 73.4x trailing P/E, 23.55x P/FCF and 24.8x EV/EBITDA, while the $259.04 fair value estimate implies 1.0% downside to fair value.
AbbVie completed the $10.9 billion Apogee acquisition on September 3, 2026, but expects adjusted-EPS dilution of $0.14 in 2026 and approximately $0.46 in 2027, with accretion not expected until 2032.
At June 30, 2026, AbbVie had $58.650 billion of long-term debt, $6.016 billion of current long-term debt maturities and $2.499 billion of short-term borrowings, creating financial flexibility and integration risks after the Apogee transaction.
Diversification outside immunology remains uneven: oncology revenue declined 1.5% year over year in Q2 2026 and aesthetics revenue increased only 0.3%.
Leadership & Competitive Position
Robert A. Michael
Tenure1.17 yrs
Beats guidance75% of qtrs
Capital allocationFair
Robert A. Michael has served as CEO since July 2025 and became Chairman effective July 1, 2025. Direct insider ownership is modest, with directors and executive officers collectively owning less than 1% of shares as of March 6, 2026. His capital-allocation record now includes the completed $10.9 billion Apogee acquisition, which broadens immunology pipeline exposure but is expected to be dilutive through 2031.
Competitive Moat
stable
intangible assetsbrand
AbbVie has not disclosed a current quantified market-share percentage in the reviewed research. Its Q2 2026 filing attributes Skyrizi and Rinvoq growth to continuing market-share uptake across indications, while Botox Therapeutic and Vraylar also gained share.
Competitors: Johnson & Johnson (JNJ), Amgen (AMGN), Bristol Myers Squibb (BMY), Eli Lilly and Company (LLY)
Disruption: High because Humira has already lost exclusivity and faced direct biosimilar competition, while patent challenges, regulatory requirements and competing therapies can impair branded-drug revenue.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
73.4x
74.04x
56.77x
20.9x
96.41x
P/S
7.18x
5.58x
5.04x
4.26x
6.63x
P/FCF
23.55x
17.63x
12.42x
10.9x
22.75x
P/S 7.18x vs 5yr range 4.26-6.63x (P25=4.26x, median=5.04x, P75=5.58x)
Price Outlook (5-Year)
Bear
$207
-4.8%/yr
Base
$259
-0.4%/yr
fair value
Bull
$311
3.3%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
Financial-data calendars estimate an October 30, 2026 release before market open. Results could update investors on Skyrizi and Rinvoq growth, Humira erosion, neuroscience momentum, full-year guidance and post-Apogee financing effects.
high
2028-01-01
Botox Medicare negotiated pricing implementation
CMS-negotiated Medicare prices for Botox and Botox Cosmetic are scheduled to take effect on January 1, 2028, creating a defined future pricing and profitability inflection point.
medium
Risks
Biosimilar Competition
high
Humira revenue declined 35.9% year over year to $756 million in Q2 2026 due to direct biosimilar competition following loss of exclusivity.
Patent and Regulatory Risk
high
Patent litigation, exclusivity loss, regulatory scrutiny and manufacturing requirements remain material risks. The Boey U.S. launch remained unresolved after an FDA Complete Response Letter related to manufacturing-process information, while AbbVie confirmed only European Commission and Health Canada approvals in its July 2026 release.
Leverage and Refinancing Risk
high
As of June 30, 2026, AbbVie reported $58.650 billion of long-term debt, $6.016 billion of current long-term debt maturities and $2.499 billion of short-term borrowings. The company had arranged a $10 billion 364-day term facility in connection with Apogee.
Growth Concentration
medium
Immunology and neuroscience are carrying company growth, while Q2 2026 oncology revenue declined 1.5% and aesthetics grew only 0.3%, increasing reliance on Skyrizi and Rinvoq execution.
Drug Pricing Pressure
medium
CMS selected Botox and Botox Cosmetic for Medicare drug-price negotiation in January 2026. AbbVie chose to participate, and negotiated prices are scheduled to take effect on January 1, 2028.
Growth Engines
Skyrizi Immunology Expansionscaling
Skyrizi addresses immune-mediated dermatology and inflammatory bowel disease, and generated $5.505 billion of Q2 2026 revenue, up 24.4% year over year. AbbVie has not provided a single contemporaneous company-verified TAM figure.
Rinvoq Indication Penetrationscaling
Rinvoq is expanding across immune-mediated diseases and produced $2.525 billion of Q2 2026 revenue, up 24.5% year over year. The opportunity is driven by penetration and label expansion rather than a disclosed aggregate TAM.
Neuroscience Franchise Growthscaling
Neuroscience revenue reached $3.228 billion in Q2 2026, up 20.3%, across migraine, neuropsychiatry and therapeutic neurotoxin markets. Key products include Vraylar, Botox Therapeutic, Ubrelvy and Qulipta.
Apogee Immunology Pipelineearly
The September 2026 Apogee acquisition adds late-stage atopic dermatitis and asthma assets, with additional exposure to COPD. Financial accretion is not expected until 2032.
AbbVie reported first-quarter 2026 results and updated guidance
The first-quarter update was one of the material financial and guidance developments during 2026.
2026-06-22
AbbVie announced a definitive agreement to acquire Apogee Therapeutics
The proposed transaction set up a major expansion of AbbVie's immunology pipeline and later closed for approximately $10.9 billion in cash.
2026-07-31
AbbVie reported second-quarter 2026 revenue growth of 10.2%
Revenue reached $16.990 billion, with strong growth from Skyrizi, Rinvoq and neuroscience offsetting a 35.9% Humira revenue decline.
2026-09-03
AbbVie completed its acquisition of Apogee Therapeutics
The completed approximately $10.9 billion cash acquisition adds late-stage atopic dermatitis and asthma assets but is expected to dilute adjusted EPS through 2027 and not become accretive until 2032.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is ABBV undervalued?
ABBV is currently fairly valued at $264.40 vs. our fair value estimate of $259.04 (-2% upside).
What is ABBV's fair value?
QuantHub Research estimates ABBV's fair value at $259.04 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for ABBV?
Biosimilar Competition: Humira revenue declined 35.9% year over year to $756 million in Q2 2026 due to direct biosimilar competition following loss of exclusivity. Patent and Regulatory Risk: Patent litigation, exclusivity loss, regulatory scrutiny and manufacturing requirements remain material risks. The Boey U.S. launch remained unresolved after an FDA Complete Response Letter related to manufacturing-process information, while AbbVie confirmed only European Commission and Health Canada approvals in its July 2026 release. Leverage and Refinancing Risk: As of June 30, 2026, AbbVie reported $58.650 billion of long-term debt, $6.016 billion of current long-term debt maturities and $2.499 billion of short-term borrowings. The company had arranged a $10 billion 364-day term facility in connection with Apogee.
What is the bull case for ABBV?
Q2 2026 revenue increased 10.2% year over year to $16.990 billion, led by 15.1% immunology growth to $8.786 billion. Skyrizi revenue grew 24.4% year over year to $5.505 billion and Rinvoq revenue grew 24.5% to $2.525 billion in Q2 2026, providing substantial offsets to declining Humira sales. Neuroscience revenue rose 20.3% year over year to $3.228 billion in Q2 2026, supported by Vraylar revenue of $1.071 billion, Botox Therapeutic revenue of $1.042 billion and combined Ubrelvy/Qulipta revenue
How confident is QuantHub in ABBV?
QuantHub has moderate conviction in ABBV. Research last updated 2026-09-15.